STAAR Surgical Company Earnings Call Transcripts
Fiscal Year 2026
-
Q1 saw strong revenue growth in China and the U.S., driven by EVO+ demand and targeted marketing. Guidance remains cautious due to market unpredictability, but gross margin and operating expense targets are set, with ongoing investments in innovation and infrastructure.
-
China's refractive market stabilized in 2025, with Q1 2026 showing strong demand and evolving seasonality due to military conscription. Ex-China markets grew broadly, while innovation focuses on EVO+ and ERP upgrades. Margin expansion is expected from manufacturing and process efficiencies.
-
Q1 2026 saw robust sales growth, a return to profitability, and improved margins, led by strong China performance and disciplined cost control. Management remains optimistic but cautious on guidance due to ongoing macro and geopolitical risks.
Fiscal Year 2025
-
2025 marked a transition year with cost reductions, leadership changes, and inventory normalization, setting the stage for targeted growth and profitability in 2026. Q4 net sales rose 18% year-over-year, with strong cash reserves and optimism for China and global recovery.
-
A global ophthalmic surgery leader highlighted its competitive lens technology, recent financial headwinds from China, and ongoing cost reductions. Regulatory wins and manufacturing shifts are expected to drive a rebound, with a strategic focus on expanding beyond current surgical patients.
-
Management detailed a $30 million share buyback, progress on China inventory normalization, and a cautious but optimistic outlook for 2025. China demand is stabilizing, competition is viewed as market-expanding, and R&D will focus on core material strengths.
-
Q1 2025 saw a sharp revenue decline due to minimal China sales, but ex-China markets grew 9%. Cost-cutting, inventory management, and Swiss manufacturing expansion are expected to restore growth and margins in H2 2025. Management remains confident in long-term prospects despite tariff and economic uncertainties.
Fiscal Year 2024
-
Net sales declined 3% in 2024 due to a sharp drop in China, while sales outside China grew double digits. A $27.5M China order was not recognized as revenue, impacting results, but is expected in 2025. Guidance for 2025 reflects high uncertainty in China, with global growth driven by strong performance in other regions.
-
EVO lens continues to gain market share globally despite macroeconomic headwinds, with strong growth in Japan and South Korea and stabilization in China. Initiatives to boost surgeon confidence and pricing flexibility are driving deeper engagement with key practices, setting the stage for future expansion and brand awareness efforts.
-
Q3 2024 net sales grew 10% year-over-year to $88.6 million, with strong performance in the Americas, EMEA, and APAC, despite macroeconomic headwinds in China. Fiscal 2024 guidance is maintained, and the company remains confident in long-term growth opportunities.
-
EVO ICL lens adoption continues to grow globally, with strong clinical data and market share gains, especially in China and Japan. Despite macro headwinds, record Q2 results and raised guidance reflect ongoing momentum, while management focuses on expanding U.S. indications and deepening practice engagement.
-
Record Q2 sales and margin expansion drove a raised 2024 outlook, with strong growth in the U.S., China, and key global markets. Strategic initiatives, new agreements, and investments in innovation and education are accelerating adoption and market share gains.<document- 2
-
The company is experiencing strong global growth, driven by its implantable lens for high myopia, with a focus on expanding in China and the U.S. Financial guidance remains robust, with profitability and cash flow outpacing peers. Ongoing initiatives target broader market adoption and product innovation.